Bank of America Chief Executive Brian Moynihan disclosed that the company spends over $250 million annually covering GLP-1 weight-loss drugs for its employees. Moynihan noted this expense was zero roughly five years ago but described it as a "quality investment." He cited the potential for both short-term and long-term health benefits for employees, such as reduced heart disease risk, as the primary reason for the company's expenditure.

During an interview on Wednesday, Moynihan stated that Bank of America allocates more than $250 million each year to cover the cost of GLP-1 weight-loss medications for its workforce. Despite the rapidly rising expense, he emphasized that the investment is worthwhile, representing a commitment to employee well-being. According to Moynihan, the bank sets aside over $20 billion annually for healthcare budgets covering approximately 211,000 employees; GLP-1 drugs alone now account for about 13% of total healthcare spending. "We're spending about $250 million or more on GLP-1 drugs, and four or five years ago that was zero," Moynihan told host Andrew Ross Sorkin. "We're seeing very significant positive effects from the drugs on our employees."

Demand for drugs like Ozempic and Wegovy has surged across the United States, with annual costs per person reaching thousands of dollars, putting pressure on employers. As usage increases, many self-insured companies and public institutions are either restricting coverage for these medications or debating their ability to sustain the expense. Moynihan acknowledged that some employees may leave before the company realizes long-term cost savings from improved health, but the policy is fundamentally about offering a high-value benefit. He explained that Bank of America not only provides access to the drugs but also pairs them with health coaching services to monitor weight loss progress and support lifestyle adjustments.

Beyond long-term disease prevention, recent clinical data shows these drugs offer short-term health benefits, including reduced cardiovascular events. "Seeing colleagues lose weight and improve their physical condition is very tangible," Moynihan said. The nation's second-largest bank by assets also leverages its purchasing power to negotiate lower drug prices with pharmaceutical companies and pharmacy benefit managers. "Honestly, we're working hard to negotiate with everyone to get the best possible price," Moynihan added. "But our assessment is that these drugs have both long-term health value and significant short-term health benefits, so this is a worthwhile investment."